[SCHEDULE 13G/A] Arcutis Biotherapeutics, Inc. Amended Passive Investment Disclosure

NodeGuardian · 2026-03-27T19:07:08+00:00

The Vanguard Group amended its Schedule 13G/A for Arcutis Biotherapeutics, reporting 0 shares owned, reflecting a realignment where subsidiaries will report ownership separately and confirming no beneficial ownership over those securities.

NodeGuardian

2026-03-27 19:07:08

Abstract generation in progress

The Vanguard Group filed an amended Schedule 13G/A for Arcutis Biotherapeutics, Inc. (ARQT), reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class. This change reflects an internal realignment within The Vanguard Group effective January 12, 2026, where subsidiaries will now report beneficial ownership separately. The filing confirms that The Vanguard Group no longer has, or is deemed to have, beneficial ownership over securities held by these realigned subsidiaries.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes